Novel Immuno-oncology Combination Therapies for Renal Cell Carcinoma:

Evolving Considerations for Clinical Practice

Banner Image
Video thumbnail

This activity is supported by educational grants from Pfizer Inc and EMD Serono.

A Video Spotlight Expert Panel Discussion

Featuring Nizar M. Tannir, MD, FACP (Course Director), Matthew Campbell, MD, MS, Toni K. Choueiri, MD, Lauren C. Harshman, MD

Overview

The development of novel treatments for patients with renal cell carcinoma (RCC) extends beyond immune-oncology (IO) monotherapy, to include IO/IO and IO/VEGF receptor tyrosine kinase inhibitor combinations, which hope to offer improvements and/or additional treatment options for both treatment-naïve and treatment-experienced patients. This video panel discussion among 3 internationally renowned RCC experts and clinical trial leaders covers a broad range of topics regarding the latest advancements in this field and the current clinical implications of these novel combinations, including unique adverse event profiles and particular considerations for patient selection and agent combination/sequencing.

Goal

The goal of this program is to provide community and academic medical oncologists, urologists, surgeons, and advanced practitioners (nurse practitioners, physicians’ assistants), as well as other healthcare providers who manage patients with RCC around the world, with current and practical information on the latest advances in IO mono- and combination therapies and how these agents can be used in current clinical practice.

Target Audience

This educational activity is designed meet the global educational needs of community and academic medical oncologists, urologists, surgeons, advanced practitioners, as well as other healthcare providers who manage patients with RCC around the world. No prerequisites required.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Evaluate the most recent data on the efficacy, safety, and clinical utility of IO and IO treatment combinations in RCC.
  • Evaluate the effect of selection of first-line IO and targeted therapies on the selection of second-line and beyond therapies.
  • Describe RCC clinical scenarios in which an IO therapy, IO/IO, or IO/VEGFR targeted therapy may be appropriate.
  • Propose strategies for the early detection and management of AEs related to the use of IO and IO combination therapy in patients with RCC.

Activity Release Date: April 30, 2020

Activity Expiration Date: April 30, 2021

1.5 hour(s) activity | ACCME



CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare




Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and ASiM CE, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME.

Commercial Support

This activity is supported by an educational grant from Pfizer and EMD Serono.

Faculty Disclosures

Nizar M. Tannir, MD, FACP (Chair)
Professor and Chair ad interim
Ransom Horne, Jr. Professor in Cancer Research
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Dr Tannir disclosed the following relevant financial relationships:
Advisory Committee – Nektar Therapeutics, Oncoren, Ono Pharmaceutical, Pfizer
Consultant – Bristol-Myers-Squibb, Eisai Medical Research, Eli Lilly, Exelisis, Inc, Nektar Therapeutics, Oncorena, Pfizer
Contracted Research – Bristol-Myers-Squibb, Calthera Biosicence, Eisai Inc., Exelisis, Inc, Nektar Therapeutics, Pfizer

Matthew Campbell, MD, MS
Assistant Professor
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Dr Campbell disclosed the following relevant financial relationships:
Consultant – Apricity Health, AstraZeneca, Eisai, EMD Serono, Exelixis, Genentech, Pfizer
Contracted Research – AstraZeneca/MedImmune, Exelixis, Pfizer/EMD Serono (Clinical Trial Support)
Other: Physician Education Courses – Bristol Myers Squibb, Pfizer, Roche

Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Department of Medical Oncology
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
The Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Dr Choueiri has disclosed no financial relationships.

Lauren C. Harshman, MD
Assistant Professor of Medicine – Oncology
Harvard Medical School
Co-director Kidney Cancer Program
Dana-Farber Cancer Institute and Brigham and Women’s Hospital
Boston, Massachusetts
Dr Harshman disclosed the following relevant financial relationships:
Consultant – Bayer, Corvus, EMD Serono, Exelixis, Genentech, Jounce, Medivation/Astellas, Merck, Michael J. Hennessy Associates (Healthcare Communications Company and several brands such as OncLive and PER), Novartis, Ology Medical Education, and Pfizer.
Contracted Research – Bayer, Bristol-Myers Squib, Dendreon/Valient, Endocyte (Novartis), Genentech, Jannsen, Medivation/Astellas, Merck, Pfizer, Sotio, and Takeda.
Other: Research Travel – Bayer and Genentech.

AKH Staff and Planners

Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner: has disclosed no relevant financial relationships.
Patricia Brignoni, AKH Sr. Director of Operations: has disclosed no relevant financial relationships.
Steve Eckert, AKH President & CEO, Planner: has disclosed no relevant financial relationships.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH and ASiM planners and reviewers have no relevant financial relationships to disclose.

Required hardware/software:

A computer with an internet connection Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.

Activity Instructions

The following is an interactive enduring expert panel discussion designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, the enduring expert panel, and a CME postassessment and evaluation. All 3 sections must be completed to receive CME credit. A certificate of participation will be available online immediately following successful completion of the activity.

Table of Contents

Preassessment

Novel Immuno-Oncology Combination Therapies for Renal Cell Carcinoma: Evolving Considerations for Clinical Practice

Faculty Panel

Postassessment and Evaluation


If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com. There is no fee for this activity.

Copyright 2020 ASiM CE LLC. No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publisher.